CA-PERSONALIS-INC
3.11.2021 00:03:14 CET | Business Wire | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the latest expansion of the Personalis NeXT Platform® adding several new features that are key to the understanding of the interactions between the tumor and the immune system and how they may influence a cancer patient’s response to therapy.
The new and improved features include:
- InfiltrateID™, a sophisticated analytics module that leverages the augmented gene expression data from the NeXT Transcriptome™ to detect the presence of eight immune cell populations within a tumor sample
- RepertoireID™ now incorporates the characterization of the B-cell receptor repertoire, including the computing of isotype makeup, as a complement to the previously released T-cell receptor repertoire feature
- SHERPA™, further enhancing the performance of Personalis’ leading pan-allelic neoantigen prediction algorithm recently published in the Immunopeptidomics Special Issue of the journal Molecular & Cellular Proteomics
Personalis CMO and SVP of R&D, Richard Chen, MD, said, “With the ability to identify immune cell populations in the tumor, characterize the B-cell and T-cell receptor repertoires, and better predict neoantigens, we are further expanding the NeXT Platform for additional emerging oncology biomarkers. As we recently demonstrated with our NEOPS biomarker publication, combining both tumor and immune features into a composite biomarker can lead to better stratification of patient response to cancer therapy. These new NeXT Platform features open up opportunities to further enhance composite biomarkers like NEOPS.”
These advanced machine learning and algorithmic tools paired with the unique assay design of the NeXT Platform, further Personalis’ goal of providing the most comprehensive genomic tumor profiling platform available. The NeXT Platform consolidates multiple biomarker assays into one, enabling a seamless path from translational research to companion diagnostics development.
About Personalis, Inc.
Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform ® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. In population sequencing, Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to Veterans Affairs' Million Veteran Program. To enable cancer and population sequencing, Personalis' Clinical Laboratory has been built with a focus on clinical accuracy, quality, big data, scale and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit www.personalis.com and follow Personalis on LinkedIn and Twitter .
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of InfiltrateID, RepertoireID, SHERPA, NEOPS, or the Personalis NeXT Platform, Personalis’ business opportunities, leadership, plans, vision or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102006387/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Launches Omni-Bos™ PHY to Help Dairy Producers Get More Value from Feed17.9.2026 13:00:00 CEST | Press release
New phytase technology unlocks nutrients already present in feed to improve efficiency, profitability and sustainability IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — today announced the launch of Omni-Bos™ PHY, a novel phytase enzyme designed specifically for dairy cattle. The technology helps producers improve nutrient utilization and feed efficiency by unlocking nutrients already present in feed, enabling cows to derive greater value from existing feed ingredients. Omni-Bos™ PHY will initially launch in the Middle East, Africa and Asia-Pacific regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916599752/en/ IFF has launched Omni-Bos™ PHY, a phytase enzyme developed specifically for dairy cattle, that helps producers unlock nutrients already present in feed to improve nutrient utilization and feed efficiency. “We believe the future of dairy nutrition is helping cows receive m
EdgeConneX Appoints SVP of Global Construction Delivery, Vice Presidents for Norway and Germany17.9.2026 13:00:00 CEST | Press release
New leaders to drive customer delivery and success, market development and growth, and community engagement EdgeConneX®, a global leader in Build-to-Suit and Build-to-Density digital infrastructure solutions, today announced the appointments of Garry O’Leary as SVP, Delivery, Global, Anders Hilt as Vice President of Norway, and Michael Barth as Vice President of Germany. All three hires bring a deep commitment to building strong local relationships and will play a key role in advancing the company's global projects and supporting community engagement and local support efforts. EdgeConneX continues to expand its platform globally, with gigawatts of major projects underway across multiple continents. As SVP, Delivery, Global, Garry plays a critical role in delivering the company's new capacity on time and on budget, overseeing regional construction leadership, contractor and vendor management, site safety, quality assurance, and supply chain. Prior to joining EdgeConneX, Garry was Vice P
Brushing Well Is Harder Than Most People Think — New Research Confirms Why the Technology Behind Oral-B iO is the Best Way to Help You Get it Right17.9.2026 12:40:00 CEST | Press release
Ranked #1 for plaque removal and gingivitis reduction, Oral-B iO's oscillating-rotating technology, paired with its unique round brush head, delivers a superior clean that helps people brush better every day, remove more plaque, and improve their gum health for healthier teeth for life. Oral-B, the #1 toothbrush brand used and recommended by dentists worldwide, today announced new evidence reinforcing the superiority of Oral-B iO technology. In an independent 2026 peer-reviewed network meta-analysis of 19 randomized clinical studies involving more than 1,300 participants, the oscillating-rotating technology behind Oral-B iO was ranked #1 for plaque removal and gingivitis reduction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260911054017/en/ Oral-B iO9 makes a superior clean easier to achieve every day. Most people think they are brushing effectively, but brushing well is harder than it seems. Plaque often remains in the
Former Colombian President Iván Duque Appointed to Advance ICC and Carbon Measures' Global Product-Level Carbon Accounting Initiative17.9.2026 12:00:00 CEST | Press release
Duque will chair the ICC & Carbon Measures Technical Expert Panel Advisory Group, bringing policy, business and practitioner perspectives into the next phase of their work. The International Chamber of Commerce (ICC) and Carbon Measures today announced that Iván Duque Márquez, former President of Colombia, has been named Chair of the newly created Technical Expert Panel Advisory Group established to complement the work of the TEP on Carbon Accounting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915635710/en/ The TEP, co-convened by ICC and Carbon Measures, brings together recognized experts from academia, financial accounting, industry and civil society to develop a globally applicable carbon emissions accounting framework. The TEP’s work comes amid growing global momentum toward harmonization of carbon accounting. The Advisory Group was created to take the TEP’s technical work to the next level, broadening engagement
Thales Unveils HexaForce: AI-Powered, Sovereign Command and Control for NATO and Allied Nations17.9.2026 12:00:00 CEST | Press release
Built on an open, interoperable architecture co-designed with armed forces, HexaForce was successfully tested during NATO CWIX 2026. HexaForce is tailored for high-intensity warfare, supporting command requirements for over 100,000 personnel where operational tempo requires the extensive, targeted deployment of AI. Thales’ multi-domain solution (covering land, sea, air, cyber, space, and information operations) is already available. Thales, a global leader in advanced technologies across Defence, Aerospace, and Cyber & Digital, has announced the launch of HexaForce, its next-generation AI-enhanced multi-domain command and control (C2) system. Purpose-built to support national sovereignty, HexaForce provides a rapid, battle-tested response to the massive growth in operational data and the accelerating pace of conflicts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917956437/en/ HexaForce_2026©Thales “Some armed forces re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom